三个皮匠报告
最新
报告分类 研搜
BETA
政策库
自研报告
new
入驻
搜索
您的当前位置：首页 > 行业数据 > 国内生物制剂仍为ax-SpA二线疗法，TNFi和IL-17A单抗的效果表现优异
图片属性
图片格式：PNG 图片大小：246KB 图片尺寸：2133*519
同报告图片
 / 4
国内生物制剂仍为ax-SpA二线疗法，TNFi和IL-17A单抗的效果表现优异_第1页
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
国内生物制剂仍为ax-SpA二线疗法，TNFi和IL-17A单抗的效果表现优异_第2页
国内生物制剂仍为ax-SpA二线疗法，TNFi和IL-17A单抗的效果表现优异_第3页
fCDoja/lk4HlkI3np7AgfCDllYblk4HlkI0gfCDnu5noja/mlrnlvI8gfCDpnbbngrkgfCDlhazlj7ggfCBDUlMvV05Q6YCC5bqU55eH6I635om55pe26Ze0IHwgQ1JTL1dOUOmAguW6lOeXh+iOt+aJueaXtumXtCB8CnwgLS0tIHwgLS0tIHwgLS0tIHwgLS0tIHwgLS0tIHwgLS0tIHwgLS0tIHwKfCDluqbmma7liKnlsKTljZXmipcgfCDovr7lv4XlpqUgfCDnmq7kuIsgfCBJTC00Us6xIHwg6LWb6K+66I+yL+WGjeeUn+WFgyB8IDIwMTkvNi8yMCB8IC0gfAp8IOWlpemprOePoOWNleaKlyB8IFhvbGFpciB8IOearuS4iyB8IElnRSB8IOe9l+awjy/or7rljY4gfCAyMDIwLzExLzMwIHwgLSB8Cnwg576O5rOK5Yip54+g5Y2V5oqXIHwgTnVjYWxhIHwg55qu5LiLIHwgSUwtNSB8IEdTSyB8IDIwMjEvNy8yOSB8IC0gfAoK6LWE5paZ5p2l5rqQ77ya5Yy76I2v6a2U5pa577yM5Zu95rOw5ZCb5a6J6K+B5Yi456CU56m244CC
国内生物制剂仍为ax-SpA二线疗法，TNFi和IL-17A单抗的效果表现优异_第4页
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
国内生物制剂仍为ax-SpA二线疗法，TNFi和IL-17A单抗的效果表现优异_第5页
所属报告： 智翔金泰-公司首次覆盖报告：自免新药获批在即双抗开启蓝海市场-231122（35页）.pdf
打包全文图表

相关数据

最新数据
全行业研究报告分享下载平台
  • 0731-84720580
  • 商务合作：really158d
关于我们
更多
关于我们
三个皮匠报告微信公众号
三个皮匠报告微信小程序
扫码咨询商务合作事宜
copyright@2008-2013 长沙思想领动信息技术有限公司版权所有        网站备案/许可证号：湘B2-20190120 | 工信部备案号：湘ICP备2023027541号-2 | 公安备案号：湘公网安备43010402001071号
客服
商务合作
小程序
服务号
折叠